Abstract. Computer simulations of the human α 1d -adrenergic receptor (α 1d -AR) based on the crystal structure of rhodopsin have been combined with experimental site-directed mutagenesis to investigate the role of residues in the transmembrane domains in antagonist binding. Our results indicate that the amino acids Asp176 in the third transmembrane domain (TMD), Glu237 in TMD IV, and Ser258 in TMD V of α 1d -AR were directly involved in prazosin and tamsulosin binding. The Asp176Ala mutant did not exhibit any affinity for [ Competition binding experiments showed that prazosin affinity had increased to 5-fold and 3-fold in the Glu237Ala and Ser258Ala mutants, respectively, versus wild-type; and tamsulosin affinity only increased in the Ser258Ala mutant (2-fold vs wild-type). It seems that these two residues constrain the receptor by interaction with other residues and this disruption of the interaction increased the receptor's binding affinity towards antagonists. However, the Glu237Ala and Ser258Ala mutant receptors retained the ability to stimulate the formation of myo-[ 3 H]inositol but had activities lower than that of the wild-type receptor. The present results provide direct evidence that these amino acid residues are responsible for the interactions between α 1d -AR and the radioligand [ 
Introduction α 1 -Adrenergic receptors (α 1 -AR) are members of the G protein-coupled receptor (GPCR) superfamily that is activated by the neurotransmitter norepinephrine, which is released from the sympathetic nerve endings, and by the neurohormone epinephrine, which is released from the adrenal medulla (1) . GPCRs are structurally characterized by seven transmembrane α-helices connected by alternating extracellular and intracellular loops. Three α 1 -AR subtypes have been cloned and pharmacologically characterized: α 1a (2, 3), α 1b (4), and α 1d (5, 6) . Many human tissues such as brain, heart and vascular smooth muscles express α 1 -AR (7) . Contraction of large caliber-type arteries have been found to be controlled by the α 1d -AR (8) .
The agonist binding pockets (9 -13) and antagonist binding pockets of α 1a -and α 1b -AR (14 -16) have been extensively studied, but antagonist binding residues on the α 1d -AR are yet to be explored. We now report the importance of three amino acid residues near the extracellular surface of the transmembrane domains (TMD) of III, IV, and V involved in non-selective binding for prazosin and tamsulosin.
Previous molecular modeling studies of α 1d -AR in our laboratory (17) predicted that the amino group of prazosin and tamsulosin make electrostatic interactions with the carboxylate side chain of Asp176 in TMD III, which is highly conserved in all GPCR-binding amine ligands. This aspartate is involved in high-affinity binding of agonists as well as antagonists at both the β 2 -(18) and α 2A -AR (19) . The sulphonamide nitrogen of tamsulosin on the other hand, would interact with Glu237 in TMD IV of α 1d -AR, and the methoxy oxygen of the benzene ring may interact with Ser258 in TMD V. 1-Nitrogen atom on the quinazoline ring of prazosin has been predicted to interact with Ser258 in TMD V.
We, therefore, constructed and characterized alanine mutations of these amino acid residues by site-directed mutagenesis. Our findings are consistent with the molecular modeling data and suggest that these amino acid residues are important for prazosin and tamsulosin binding. Prazosin and tamsulosin showed significant increases in binding affinity towards the Ser258Ala mutant and only prazosin showed increased affinity for the Glu237Ala mutant in competition binding experiments. These increases in affinity may be caused by disruption of receptor constraints by mutations of the glutamate and serine residues that would otherwise make bridges with other residues on different transmembrane domains of this receptor.
Materials and Methods

Drugs
Prazosin and tamsulosin were obtained from RBI (Research Biochemical, Inc., Natick, MA, USA). All other chemicals used were of the highest purity available.
DNA constructs
A cDNA clone encoding human α 1d -AR receptor in the plasmid vector (pCR3) was introduced into the DH5α strain of E. coli by the electroporation. The culture of E. coli was used to prepare plasmid DNA by the plasmid purification midi kit (Qiagen, Hilden, Germany). α 1d -AR-receptor mutants were constructed with the Quick Change Site-Directed Mutagenesis Kit (Stratagene USA, La Jolla, CA, USA). The mutations were confirmed by sequencing the mutation site in the expression vector.
Cell culture and transfection
HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U / ml penicillin, and 100 µg/ ml streptomycin. HEK293 cells were transfected with each of the wild-type and mutant receptors in 10-cm dishes at about 80% confluence with Polyfect Transfection Reagent using the manufacturer's protocol (Qiagen, Valencia, CA, USA). At 24 h after transfection, the selection for stably expressed cells was done for two weeks in the medium containing 10% fetal bovine serum and 500 µg / ml G418. Stably expressing cell lines were subsequently cultured in 200 µg / ml G418-containing growth medium.
Membrane preparations from HEK293 cells
For the preparation of membranes, cell pellets were thawed and homogenized in 1 ml of 50 mM Tris-HCl (pH 7.4) and 1 mM EDTA-Na with a Polytron homogenizer (setting 7 for 8 s). The homogenates were centrifuged at 3000 rpm for 5 min. The supernatant were further centrifuged at 30,000 rpm for 30 min. The precipitate was resuspended into binding buffer. Protein content was measured by the method of Bradford (20) .
Ligand binding assays
Stably H]prazosin with wild-type receptors was 100 pM and 6 concentrations of competing ligands were used in duplicate. Because mutation of the α 1d -AR resulted in a reduced affinity for [
3 H]prazosin, competition studies for the Asp137Ala, Glu237Ala, and Ser258Ala mutants were carried out with 500 pM [
3 H]prazosin. Nonspecific binding was defined with the use of 1 nM tamsulosin. For both the radioligand binding assays, incubations were carried out for 45 min at 30°C and were terminated by rapid filtration through Whatman GF / C filters that had been presoaked in 0.3% polyethyleneimine followed by washing with 10 ml ice-cold wash buffer. The radioactivity retained on the filters was quantitated by liquid scintillation spectrophotometry.
Phosphatidylinositol hydrolysis assay
Stably transfected HEK293 cells were seeded into 24-well plates and labeled with 5 µCi / ml myo-[ 
H]inositol phosphates ([
3 H]IP) was assayed as described previously (21) . In brief, after labeling, cells were washed twice with KHL buffer to remove unincorporated radioactivity. Then, cells were preincubated for 15 min in KHL buffer with 10 mM LiCl in the presence or absence of tested drugs and various concentration of phenylephrine for 1 h.
The reactions were terminated by addition of ice-cold 10% perchloric acid and were cooled for 20 min at 4°C. The samples were neutralized with 200 mM KOH and 50 mM Tris and were centrifuged. The resulting supernatant was applied to 1 ml of AG1-X8 resin (100 -200 mesh, chloride form; Bio-Rad, Hercules, CA, USA). Total IP were eluted with 1 ml of 1N HCl and were estimated in a liquid scintillation counter.
Data analysis
Nonlinear regression analysis of saturation and competition binding assay were performed using GraphPad Prism software (San Diego, CA, USA). Statistical analyses were performed by Student's t-test. The agonist EC 50 values and antagonist IC 50 values of the concentration-response curve were calculated by nonlinear analysis using GraphPad Prism software. pA 2 value was determined using the following equation: Table 1) . The expression level for a given construct was found to be consistent in separate preparations.
Competition experiment
The affinities (pK i values) of prazosin and tamsulosin for both the wild-type and mutant receptors were determined in competition binding experiments for sites labeled with [
3 H]prazosin. Surprisingly, the pK i values of prazosin and tamsulosin in the Glu237Ala and Ser258Ala mutants of α 1d -AR were increased. The other mutant, Asp176Ala, had no affinity for any of the antagonists (Fig. 1) .
Agonist-stimulated IP accumulation
The wild type and mutant receptors were expressed in stably transfected HEK293 cells, and the concentrationresponse curves for phenylephrine stimulated IP accumulation were determined. The pA 2 values measured for phenylephrine on the wild-type receptor as well as Glu237Ala and Ser258Ala mutants are given in Table 2 . However, the mutation of Asp176Ala eliminated detectable IP accumulation. The pA 2 values of the Glu237Ala and Ser258Ala mutants for the ligands tamsulosin and prazosin were decreased significantly as shown in Table 2 . Discussion α 1d -Adrenergic receptors seem to play key roles in the regulation of the vascular tone responsible for the maintenance of blood pressure. There is a large amount of evidence that suggest that they participate in the pathogenesis of hypertension in different rodent models (reviewed in ref. 22 ). So, the antagonists of α 1d -AR are useful for treating cardiovascular diseases occurring due to α 1 -ARs. Recently, with the development of computerbased homology modeling, the three dimensional structure of receptors of cardiac muscles and blood vessels and their binding with ligands could be anticipated. The binding sites of the receptor complex and the analysis of the binding profile were made possible by these developments.
As for the binding sites for prazosin and tamsulosin in α 1d -AR, it is evident that amino acids on the 3rd, 4th, and 5th TMDs of α 1d -AR are important according to a study that analyzed the binding sites with the receptor by computer-based homology modeling (17) . Especially, Asp176, Glu238, and Ser258 on α 1d -AR are supposed to interact with α 1 -AR antagonists. Therefore, in this study, we constructed and characterized the mutations of these amino acid residues by site-directed mutagenesis. These amino acids were replaced by alanine. Since alanine substitutions introduce changes in both charge and Hbonding capabilities and in size, potentially leaving a cavity in comparison to other side chains, these three amino acids were substituted by alanine. Evaluation of the mutant receptor using both ligand binding and functional assays of coupling to signal transduction provides an insight into the basis of the various functional effects observed following introduction of a mutation. We, therefore, analyzed the mutant receptors by both ligand binding and signal transduction assays. The effects of the mutations studied on the affinity of prazosin and tamsulosin correlated fully with the expectations from the computational modeling of these antagonists with the α 1d -AR.
In the study with α 1d -AR, the low receptor density in the cell line was unsatisfying but not unexpected. It has been observed that α 1d -ARs expression is not high in vivo, to the extent that even their presence in rat tissues had been questioned (23) . It is also low in transfected cell lines and it has been observed that truncation of the N-terminus increases the detection of receptors (but not protein), which has lead to the suggestion that the processing of this receptor might encounter difficulties in some cells (24) .
Effects of Asp176Ala mutant on antagonist binding to α 1d -AR Early studies with the β-AR suggested that the agonist binding pocket was constituted by the interaction of the protonated amine of the catecholamine that hydrogen bonds to an aspartate residue in TMD III. Both agonist and antagonist binding are more severely affected by mutation of the aspartate in TMD III of the β-AR (25) . It can be argued that mutants of this residue are highly unstable and very little surface expression occurs, making binding analysis difficult.
In previous mutagenesis studies of the β 2 - (18) and α 2A -AR (19) the authors suggested that the amino group of the catecholamines makes an electrostatic interaction with the carboxylate side chain of an aspartate on TMD III, which is highly conserved in all GPCR binding amino ligands. Furthermore, Asp125 of the α 1b -AR is the homologous to the aspartate on TMD III of β 2 -and α 2A -AR and the dopamine 1 -receptor involved in the interaction with the amino group of catecholamines (13). Cavalli and co-workers reported that mutation of Asp125 to alanine totally impaired the ability of the α 1b -AR to bind both agonists and antagonists. This was shown by the fact that Asp125Ala displayed no specific [ 125 I]HEAT binding and no epinephrine-induced stimulation of IP production (13) . Another report mentioned that a negative charge at position 125 on TMD III is thought to be important for agonist as well as antagonist affinity at β-and α 2 -ARs (26). Recently, similar results for α 1b -AR were obtained in our laboratory (27) . Mutation of the same conserved aspartate residue on 5-HT 2C and 5-HT 2B also showed no ligand binding or 5-HT stimulated IP formation in our laboratory (28, 29) . These results may be extrapolated to the conserved aspartate at position 176 in α 1d -AR. In the present study, we also report that mutation of Asp176Ala in α 1d -AR eliminated [ 3 H]prazosin as well as tamsulosin binding and phenylephrine stimulated IP formation. These results strongly suggest that the same conserved aspartate Asp176 on TMD III of α 1d -AR interacts with the functional amino group of prazosin and tamsulosin. Effects of Ser258Ala mutant on antagonist binding to α 1d -AR Ser258, Ser259, and Ser262 in TMD V of the α 1d -AR are homologous to the cluster of two to three serines conserved in TMD V of GPCRs that bind catecholamines with high affinity (Fig. 2) . Ser204 and Ser207 of β 2 -AR (18) and Ser188 and Ser192 of α 1a -AR (12) are supposed to interact with meta-and para-hydroxyl groups of catecholamines, respectively. Using the substituted cysteine accessibility method, it was found that in addition to Ser204 and Ser207 in β 2 -AR, Ser203 is also accessible in the binding crevice and that both Ser203 and Ser204 appear to interact with the metahydroxyl group of catecholamines, perhaps through a bifurcated hydrogen bond (30) . In α 1b -AR, mutation of Ser207 (analogous to Ser258 in α 1d -AR, Fig. 2 ) to alanine decreased the agonist binding, without changing the binding of the antagonist prazosin (13) . Although, Ser208 mutation to alanine did not affect the agonist binding, Ser211 interacted with meta-hydroxyl group of catecholamine. So far conserved serines on TMD V in different GPCRs have been found to interact with agonists.
In contrast to the above results, Ser258 is likely to interact with prazosin and tamsulosin, which have been confirmed by ligand binding affinity and agoniststimulated IP formation assay in our study. Ser258 mutation to alanine increased Effects of Glu237Ala mutant on antagonist binding to α 1d -AR Similar to the mutation of Ser258 in TMD V or Glu237 in TMD IV also resulted in increased binding affinity to prazosin and tamsulosin in [ 3 H]prazosin displacement studies. As proposed in the literature by Ishiguro et al. (17) , Glu237 in TMD IV of α 1d -AR being negatively charged might form a salt bridge with the nearby positively charged Lys236 or with other amino acid residues on different transmembrane portions of the enzyme. As a result, the increased pK i values of prazosin and tamsulosin might be the result of the breakdown of this "receptor constrain" by the chemically unreactive, hydrophobic alanine mutation. Therefore, it can be assumed that this amino acid could be necessary for binding prazosin and tamsulosin. However, it appeared that the functional efficacy of antagonists was significantly decreased by the mutation and is evident from the difference of pA 2 values for prazosin and tamsulosin for the wild-type receptor and mutant receptor. This might be the result of the coupled state of the receptor to G-proteins that had reduced the efficacy of antagonist binding to the receptor.
Studies suggested that in contrast to agonist binding, which is localized to the interior core of the receptor, antagonists interact with residues closer to the extracellular surface of adrenergic receptors, above the plane of agonist binding pocket (14, 32, 33) . In this study, we also confirm that the antagonist binding pocket is near the surface of the receptor and not down into the ligandbinding pocket like the binding site for agonists (Fig. 3) . α 1 -Adrenergic receptor antagonists tend to be much larger than agonists (as much as two to four times larger) and comparable in size to peptide ligands. The size difference may be the reason for the antagonists' tendency to bind to the surface of the receptor and antagonize by blocking the agonist-binding pocket (reviewed in ref. 34 ).
In conclusion, our studies showed that a combination of computer modeling, site-directed mutagenesis, and pharmacological analysis was helpful to explore whether Asp176, Glu237, and Ser258 in TMD III, IV, and V, respectively, of α 1d -AR are involved in prazosin and tamsulosin binding.
